South Korea Antibody Drug Conjugates Market Size & Outlook
Related Markets
South Korea antibody drug conjugates market highlights
- The South Korea antibody drug conjugates market generated a revenue of USD 241.0 million in 2024 and is expected to reach USD 717.3 million by 2033.
- The South Korea market is expected to grow at a CAGR of 12.9% from 2025 to 2033.
- In terms of segment, breast cancer was the largest revenue generating application in 2024.
- Urothelial Carcinoma is the most lucrative application segment registering the fastest growth during the forecast period.
Antibody drug conjugates market data book summary
| Market revenue in 2024 | USD 241.0 million |
| Market revenue in 2033 | USD 717.3 million |
| Growth rate | 12.9% (CAGR from 2025 to 2033) |
| Largest segment | Breast cancer |
| Fastest growing segment | Urothelial Carcinoma |
| Historical data | 2021 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Breast Cancer, Blood Cancer, Urothelial Carcinoma, Ovarian Cancer |
| Key market players worldwide | Pfizer Inc, Takeda Pharmaceutical Co Ltd, AstraZeneca PLC, Roche Holding AG, Gilead Sciences Inc, Daiichi Sankyo Co Ltd, GlaxoSmithKline Consumer Healthcare (GSK CH India), Astellas Pharma Inc, ADC Therapeutics SA |
Other key industry trends
- In terms of revenue, South Korea accounted for 2.0% of the global antibody drug conjugates market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Asia Pacific, China antibody drug conjugates market is projected to lead the regional market in terms of revenue in 2033.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 1,442.0 million by 2033.
Breast cancer was the largest segment with a revenue share of 40.95% in 2024. Horizon Databook has segmented the South Korea antibody drug conjugates market based on breast cancer, blood cancer, urothelial carcinoma, ovarian cancer covering the revenue growth of each sub-segment from 2021 to 2033.
South Korean pharmaceutical company Alteogen offers cutting-edge programs for the development of ADC drugs. It currently has an ADC drug (ALT-P7) for breast/gastric cancer, which completed phase 1 trial and demonstrated high tolerability and disease control rate in May 2020. ALT-Q5 is indicated for ovarian cancer and is in the preclinical phase.
Other companies are forming research collaborations to advance the development of ADC drugs in South Korea. For instance, in January 2021, Pharm Abcine Inc., a clinical-stage biotechnology company focused on the development of human antibody therapeutics, entered into a research collaboration with South Korean company Lego Chem Bio Sciences, Inc., which is focused on R&D in ADCs.
Under this agreement, Pharm Abcine will provide Lego Chem Bio Sciences its preclinical drug PMC-403, for combination research on LCB’s proprietary ADC technology platform. As per the World Cancer Research Fund, South Korea had the highest prevalence of stomach cancer in the world in 2018. Kadcyla and Adectris are the most commonly used ADCs.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antibody Drug Conjugates Market Scope
Antibody Drug Conjugates Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| ADC Therapeutics SA | View profile | 274 | Route de la Corniche 3B, Biopole, Epalinges, Switzerland, 1066 | https://www.adctherapeutics.com |
| GlaxoSmithKline Consumer Healthcare (GSK CH India) | View profile | 1001-5000 | Gurgaon, Haryana, India, Asia | https://india-consumer.gsk.com/ |
| Astellas Pharma Inc | View profile | 14484 | 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan, 103-8411 | http://www.astellas.com |
| Daiichi Sankyo Co Ltd | View profile | 17435 | 3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, Japan, 103-8426 | https://www.daiichisankyo.com |
| Takeda Pharmaceutical Co Ltd | View profile | 49095 | 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 | https://www.takeda.com |
| Gilead Sciences Inc | View profile | 18000 | 333 Lakeside Drive, Foster, CA, United States, 94404 | https://www.gilead.com |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| Roche Holding AG | View profile | 103605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | https://www.roche.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
South Korea antibody drug conjugates market size, by application, 2021-2033 (US$M)
South Korea Antibody Drug Conjugates Market Outlook Share, 2024 & 2033 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
